Buy & Sell Applied Materials, Inc. (AMAT) – Applied Materials, Inc. Price Today
Aura AI Summary
Key Stats
- $346.51BMarket Cap
- TechnologySector
- -18.17%3M Drawdown
- $344.72BEnterprise Value
- 0.49%Dividend Yield
- 75 daysTypical Hold Time
Applied Materials, Inc. (AMAT) is currently valued at a market capitalization of $346.51B, with an enterprise value of $344.72B. Over the past 52 weeks, Applied Materials, Inc. has traded between a low of $156.25 and a high of $443.62, highlighting its annual price range. Over the past three months, Applied Materials, Inc. has recorded a drawdown of -18.17%, reflecting recent price volatility. Applied Materials, Inc. offers a dividend yield of 0.49%, with the most recent dividend of $0.46 paid on 19 Feb 26. On average, investors hold Applied Materials, Inc. for approximately 75 days, indicating typical investor behavior on the platform.
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Most Recent News
SuperCom wins new electronic monitoring contract in Nevada, expanding to 17 U.S. states since mid-2024.
SuperCom secured a new electronic monitoring contract in Nevada, marking its entry into the state and expanding its U.S. presence to 17 states since mid-2024. The contract involves deploying SuperCom's PureOne GPS technology for offender supervision,...
Sitryx Therapeutics to present at major healthcare investor conferences in June 2026
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron shares drop 10% after Phase 3 melanoma trial misses primary endpoint.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
